Page 12 - Klaus Sindahl News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Hansa Biopharma to host conference call to provide interim results for January-March 2023 and a Business Update

/PRNewswire/ Hansa Biopharma AB (Nasdaq Stockholm: HNSA) will publish its interim report for January-March 2023 at 8:00 CET on April 20, 2023. All.

United statesUnited kingdomNoord hollandVastra gotalands lanHansa biopharmaDonato spotaStephanie kenneyKlaus sindahlErik penser company dayVp global corporate affairsVan lanschot kempen life sciences conferenceRedeye investor forumNasdaq stockholmInterim reportMidcap canadaPenser company day

Hansa Biopharma completes enrollment in phase 2 study of imlifidase in Guillain-Barré Syndrome (GBS)

Hansa Biopharma completes enrollment in phase 2 study of imlifidase in Guillain-Barré Syndrome (GBS)
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United kingdomHansa biopharmaKlaus sindahlStephanie kenneyShahram attarianVp global corporate affairsInternational coordinating principal investigatorDrug administrationInternational guillain barrErasmus medical centreHead of department neuromuscular diseasesNasdaq stockholmSyndrome outcome studyNeuromuscular diseasesHopitaux universitaires de marseilleOrphan drug designation

Hansa Biopharma publishes Annual Report 2022

/PRNewswire/ Hansa Biopharma AB "Hansa" (STO TIDM: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced the release of.

United kingdomPrnewswire hansa biopharmaStephanie kenneyKlaus sindahlHansa biopharmaEuropean society for organ transplantationVp global corporate affairsAnnual reportEuropean societyOrgan transplantationEuropean post approval efficacy studyDuchenne muscular dystrophySarepta therapeuticsGreat placeSustainability reportSecurities markets

Hansa Biopharma announces positive reimbursement decision in Spain for Idefirix® (imlifidase) as desensitization treatment for highly sensitized patients in kidney transplantation

/PRNewswire/ Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced that the.

United kingdomComunidad autonoma de catalunaHansa biopharmaOriol bestardKlaus sindahlStephanie kenneyPrnewswire hansa biopharmaHebron university hospitalEuropean medicines agency ema priorityEuropean unionEuropean medicines agencyHealth ministerio de sanidadVp global corporate affairsNasdaq stockholmSpanish ministerMinisterio de sanidad

Matthew Shaulis appointed Chief Commercial Officer and US President of Hansa Biopharma

/PRNewswire/ Hansa Biopharma, "Hansa" (NASDAQ Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, announced today that.

United statesHansa biopharmaPrnewswire hansa biopharmaStephanie kenneyKlaus sindahlMatthew shaulisHenk doude van troostwijkImmunology for the international developedHansa biopharma incVp global corporate affairsChief commercial officerHenk doudeVice presidentCommercial excellenceInternational developed marketsNorth america oncology